<DOC>
	<DOCNO>NCT00670878</DOCNO>
	<brief_summary>This open-label , multicenter randomize control , Phase III study compare disease free survival randomisation patient treat 3 cycle Epirubicin-Fluorouracil-Cyclophosphamide ( FEC ) -chemotherapy , follow 3 cycle Docetaxel ( D ) -chemotherapy versus 3 cycle Epirubicin-Fluorouracil- Cyclophosphamide ( FEC ) , follow 3 cycle Gemcitabine-Docetaxel ( DG ) - chemotherapy . Patients require HER2-neu positive disease histopathological proof axillary lymph node metastasis ( pN1-3 ) high risk node negative , define : pT &gt; =2 histopathological grade 3 , age &lt; = 35 negative hormone receptor ' , allow evidence distant disease . Patients enter study later 6 week complete resection primary tumor . No antineoplastic treatment surgical treatment , define cytotoxic endocrine treatment radiotherapy allow prior study entry course study .</brief_summary>
	<brief_title>Studying Benefits Adjuvant Sequential v . Combined Taxane Based Chemotherapy , Followed Different Biological Treatment Strategies Early , HER2-positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Primary epithelial invasive carcinoma breast pT14 , pN03 , M0 Evidence HER2neu overexpressing ( IHC +++ ) amplifying ( FISH + ) tumor Histopathological proof axillary lymph node metastasis ( pN13 ) high risk node negative , define least two criterion follow : 'pT³2 , histopathological grade 3 , age £ 35 , negative hormone receptor ' Complete resection primary tumor margin resection free invasive carcinoma 6 week ago Females &gt; = 18 year age Performance Status &lt; 2 ECOGScale Adequate bone marrow reserve : leucocytes ³ 3.0 x 109/l platelet ³ 100 x 109/l Bilirubin within one fold reference laboratory 's normal range , ASAT ( SGOT ) , ALAT ( SGPT ) AP within 1,5 fold reference laboratory 's normal range patient Intention regular follow visit duration study Ability understand nature study give write informed consent Women childbearing potential must agree use effective method contraception ( PearlIndex &lt; 1 , e.g . , intrauterine device sterilization ) treatment least 6 month thereafter . Inflammatory breast cancer Previous concomitant cytotoxic systemic antineoplastic treatment part study A second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) Cardiomyopathy impair ventricular function ( NYHA &gt; II ) , cardiac arrhythmia influence LVEF require medication , history myocardial infarction angina pectoris within last 6 month , arterial hypertension control medication Any know hypersensitivity reaction docetaxel , epirubicin , cyclophosphamide , gemcitabine medication include study protocol . The contraindication , warn notice measure precaution product , notify product information , respect Instable diabetes mellitus , sufficient medical control Use investigational agent within 3 week prior inclusion Patients pregnancy breast feeding ( premenopausal woman contraception assure )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>